April 7, 1:00 p.m.
Fireside Chat with Max Wallace and Don Lo
April 7th ; 1:00 PM
Okey Patteson Auditorium
Max Wallace and Don Lo are joining us on April 7th for a free ranging Fireside Chat about their experiences launching successful life science companies from academic institutions, work they have done in commercializing breakthrough discoveries, and research and their views on the role academia plays in bringing cutting edge treatments to patients.
Max is CEO of Accelerate Brain Cancer Cure, and was previously: CEO of TheraLogics (cancer therapeutics), Founder and President of Trimeris (HIV Therapeutics), Founder Cogent Neuroscience, Sphinx Pharmaceuticals, and SARCO. He is an active board member of tissue engineering company, Humacyte – Fast company referenced them as one of the 10 most innovative biotech companies in the US and they recently completed a $150 Million financing.
Don is Director of the Center for Drug Discovery at Duke University and Associate Professor of Neurobiology at Duke Medical Center. He has been engaged in basic science and drug discovery research for neurological diseases for over 25 years. Don was Co-founder and Chief Science Officer of Cogent Neuroscience until 2002 when he returned to Duke to establish Duke’s Center for Drug Discovery.
Come celebrate with the WVU community and special guests on April 7, 4:30 p.m. at the Blanchette Rockefeller Neurosciences Institute as we open the doors to WVU’s new “Health Sciences Innovation Center.”
This is the new home of our life sciences technology transfer team, and includes incubation wet labs for WVU's growing roster of life sciences startups. Tour the labs and meet some of the life sciences startups that are beginning to be incubated at the Health Sciences Innovation Center.
For more information, please contact:
Director Health Sciences Innovation, Entrepreneurship, and Commercialization
2268 Health Sciences South
The WVU Cancer Institute held its annual Pink Party event on Monday, September 10, to benefit Bonnie’s Bus, the mobile mammography unit that travels across West Virginia to provide mammograms to the women of the state.
WVU Cancer Institute offering groundbreaking treatment for gastroenteropancreatic neuroendocrine tumors
The WVU Cancer Institute is participating in the implementation of a new drug therapy for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), a type of tumor that can form in the pancreas or in other parts of the gastrointestinal tract, including the stomach, small intestine, colon, rectum, and appendix. These life-threatening tumors can spread to other organs, such as the liver.
Meshea Poore, vice president for the Division of Diversity, Equity and Inclusion at WVU, will be the special guest at a Health Sciences Town Hall during WVU’s Diversity Week celebrations.